627 related articles for article (PubMed ID: 18258859)
1. Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension.
Letavernier E; Perez J; Bellocq A; Mesnard L; de Castro Keller A; Haymann JP; Baud L
Circ Res; 2008 Mar; 102(6):720-8. PubMed ID: 18258859
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.
Zhong J; Basu R; Guo D; Chow FL; Byrns S; Schuster M; Loibner H; Wang XH; Penninger JM; Kassiri Z; Oudit GY
Circulation; 2010 Aug; 122(7):717-28, 18 p following 728. PubMed ID: 20679547
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective effects of granulocyte colony-stimulating factor in angiotensin II-induced cardiac remodelling.
Jia N; Dong P; Huang Q; Jin W; Zhang J; Dai Q; Liu S
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):262-6. PubMed ID: 18785976
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.
Weisberg AD; Albornoz F; Griffin JP; Crandall DL; Elokdah H; Fogo AB; Vaughan DE; Brown NJ
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):365-71. PubMed ID: 15576638
[TBL] [Abstract][Full Text] [Related]
5. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
Neves MF; Amiri F; Virdis A; Diep QN; Schiffrin EL;
Can J Physiol Pharmacol; 2005 Nov; 83(11):999-1006. PubMed ID: 16391708
[TBL] [Abstract][Full Text] [Related]
6. Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice.
Peltier J; Bellocq A; Perez J; Doublier S; Dubois YC; Haymann JP; Camussi G; Baud L
J Am Soc Nephrol; 2006 Dec; 17(12):3415-23. PubMed ID: 17082241
[TBL] [Abstract][Full Text] [Related]
7. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling.
Ishibashi M; Hiasa K; Zhao Q; Inoue S; Ohtani K; Kitamoto S; Tsuchihashi M; Sugaya T; Charo IF; Kura S; Tsuzuki T; Ishibashi T; Takeshita A; Egashira K
Circ Res; 2004 May; 94(9):1203-10. PubMed ID: 15059935
[TBL] [Abstract][Full Text] [Related]
8. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency.
Yagi S; Aihara K; Ikeda Y; Sumitomo Y; Yoshida S; Ise T; Iwase T; Ishikawa K; Azuma H; Akaike M; Matsumoto T
Circ Res; 2008 Jan; 102(1):68-76. PubMed ID: 17967781
[TBL] [Abstract][Full Text] [Related]
9. Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT/mTOR, ERK1/2, NF-κB, and calcineurin signaling pathways in mice.
Wang AW; Song L; Miao J; Wang HX; Tian C; Jiang X; Han QY; Yu L; Liu Y; Du J; Xia YL; Li HH
Am J Hypertens; 2015 Apr; 28(4):518-26. PubMed ID: 25362112
[TBL] [Abstract][Full Text] [Related]
10. Alpha2-antiplasmin is a critical regulator of angiotensin II-mediated vascular remodeling.
Hou Y; Okada K; Okamoto C; Ueshima S; Matsuo O
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1257-62. PubMed ID: 18436805
[TBL] [Abstract][Full Text] [Related]
11. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.
Diep QN; Benkirane K; Amiri F; Cohn JS; Endemann D; Schiffrin EL
J Mol Cell Cardiol; 2004 Feb; 36(2):295-304. PubMed ID: 14871557
[TBL] [Abstract][Full Text] [Related]
12. Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production.
Bao W; Behm DJ; Nerurkar SS; Ao Z; Bentley R; Mirabile RC; Johns DG; Woods TN; Doe CP; Coatney RW; Ohlstein JF; Douglas SA; Willette RN; Yue TL
J Cardiovasc Pharmacol; 2007 Jun; 49(6):362-8. PubMed ID: 17577100
[TBL] [Abstract][Full Text] [Related]
13. Nuclear factor-kappaB signaling contributes to severe, but not moderate, angiotensin II-induced left ventricular remodeling.
Sármán B; Skoumal R; Leskinen H; Rysä J; Ilves M; Soini Y; Tuukkanen J; Pikkarainen S; Lakó-Futó Z; Sármán B; Papp L; deChâtel R; Tóth M; Ruskoaho H; Szokodi I
J Hypertens; 2007 Sep; 25(9):1927-39. PubMed ID: 17762659
[TBL] [Abstract][Full Text] [Related]
14. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice.
Dikalova A; Clempus R; Lassègue B; Cheng G; McCoy J; Dikalov S; San Martin A; Lyle A; Weber DS; Weiss D; Taylor WR; Schmidt HH; Owens GK; Lambeth JD; Griendling KK
Circulation; 2005 Oct; 112(17):2668-76. PubMed ID: 16230485
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II induces vascular dysfunction without exacerbating blood pressure elevation in a mouse model of menopause-associated hypertension.
Javeshghani D; Sairam MR; Neves MF; Schiffrin EL; Touyz RM
J Hypertens; 2006 Jul; 24(7):1365-73. PubMed ID: 16794486
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II type 2 receptor gene transfer elicits cardioprotective effects in an angiotensin II infusion rat model of hypertension.
Falcón BL; Stewart JM; Bourassa E; Katovich MJ; Walter G; Speth RC; Sumners C; Raizada MK
Physiol Genomics; 2004 Nov; 19(3):255-61. PubMed ID: 15383639
[TBL] [Abstract][Full Text] [Related]
17. Blockade of NF-kappaB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II.
Kawano S; Kubota T; Monden Y; Kawamura N; Tsutsui H; Takeshita A; Sunagawa K
Cardiovasc Res; 2005 Sep; 67(4):689-98. PubMed ID: 15921667
[TBL] [Abstract][Full Text] [Related]
18. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice.
Matsuno K; Yamada H; Iwata K; Jin D; Katsuyama M; Matsuki M; Takai S; Yamanishi K; Miyazaki M; Matsubara H; Yabe-Nishimura C
Circulation; 2005 Oct; 112(17):2677-85. PubMed ID: 16246966
[TBL] [Abstract][Full Text] [Related]
19. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart.
Zhou G; Li X; Hein DW; Xiang X; Marshall JP; Prabhu SD; Cai L
J Am Coll Cardiol; 2008 Aug; 52(8):655-66. PubMed ID: 18702970
[TBL] [Abstract][Full Text] [Related]
20. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy.
Zhai P; Galeotti J; Liu J; Holle E; Yu X; Wagner T; Sadoshima J
Circ Res; 2006 Sep; 99(5):528-36. PubMed ID: 16902180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
